All In Biotech

Drug Trial Radar · NCT07157956

CVL006 Combination Therapy in Advanced Solid Tumors

Phase I/II Clinical Study of CVL006 Combination Therapy in Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Sep 5, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

318

Planned (sponsor's estimate)

Start

Sep 10, 2025

Primary completion

Aug 12, 2028

Study completion Dec 30, 2028

Sponsor

Lead sponsor
Convalife (Shanghai) Co., Ltd.Industry
Sponsor type
Industry
First posted
Sep 5, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a multi-center, open-label, dose-escalation and dose-optimized phase I/II clinical trial. Objective: To determine the safety, tolerability, PK characteristics and preliminary efficacy data of CVL006 combined with pemetrexed + carboplatin/SKB264/ DS-8201a/ Enfortumab Vedotin in patients with advanced solid tumors.

Conditions

  • Advanced Solid Tumor

Interventions

  • CVL006 combined with pemetrexed and carboplatinDrug

    CVL006 combined with pemetrexed and carboplatin

  • CVL006 in combination with SKB264Drug

    CVL006 in combination with SKB264

  • CVL006 in combination with DS-8201Drug

    CVL006 in combination with DS-8201

  • CVL006 in combination with Enfortumab VedotinDrug

    CVL006 in combination with Enfortumab Vedotin

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. DLT and RP2D of phase ITime frame: 28 days after the first medication; If the second administration is delayed, the DLT observation period will be extended to 14 days after the second administration
  2. Phase II, progression-free survival (PFS) according to RECISTv1.1 criteriaTime frame: Imaging examinations should be conducted every 8 weeks (±7 days) after the initiation of administration
  3. Safety endpoints for phase I and Phase IITime frame: From date of randomization until the date of first documented progression, assessed up to 36 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Sun Yat-sen University Cancer Center

    Guangzhou, Guangdong, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.